Investigating the role of ctDNA in advanced thyroid cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the utility of circulating tumor DNA (ctDNA) and tumor evolution in patients with advanced thyroid cancer. It will collect blood and tissue samples from participants to analyze genetic markers and tumor biomarkers that may indicate disease progression and treatment response. By understanding the genetic landscape of these tumors, the study seeks to improve personalized treatment strategies and patient stratification. The research will focus on various types of thyroid cancer, including differentiated, medullary, and anaplastic thyroid cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older. (all cohorts)
* Patients diagnosed with radioiodine refractory differentiated thyroid carcinoma (RR-DTC) under surveillance. (cohort 1)
* Patients with newly diagnosed resectable locally advanced medullary thyroid cancer Or Patients with newly diagnosed metastatic medullary thyroid cancer for surveillance Or Patients with locally advanced or metastatic medullary thyroid cancer on surveillance (cohort 2)
* Patients with RR-DTC starting systemic therapy Or Patients with RR-DTC on systemic therapy Or Patients with MTC starting systemic therapy Or Patients with MTC on systemic therapy (cohort 3)
* Patients with newly diagnosed anaplastic thyroid cancer (cohort 4)
* Availability of tissue from one archival diagnostic tumour tissue block or be willing to have biopsy of accessible disease (all cohorts)
* Patients must be willing to undergo standard monitoring and treatment as recommended by their clinical team (all cohorts)
* Ability to give informed consent for biological sample collection. (all cohorts)

Exclusion Criteria:

* Previous or concurrent illness, which in the investigator's opinion would interfere with collection of the complete sample collection
* Any invasive malignancy within previous 5 years (other than non-melanomatous skin carcinoma or carcinoma in situ)
* Pregnancy

Where it's running

• The Royal Marsden NHS Foundation Trust
  London, United Kingdom Recruiting

Study contacts

• Principal investigator: Kate Newbold — Royal Marsden NHS Foundation Trust
• Study coordinator: Leslie Cheng
• Email: leslie.cheng@rmh.nhs.uk
• Phone: 02000000000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer

  This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07777536

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

• WeChat-supported neck exercises after thyroidectomy

  A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.

  Recruiting Shanghai 6th People's Hospital · Shanghai, Shanghai Municipality · NCT07707401

• Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors

  This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.

  Recruiting at 2 sites Phase 4 Rigel Pharmaceuticals · Logroño, La Rioja and 1 other locations · NCT07704658

• AI chatbot to guide thyroid cancer patients through perioperative education

  A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07634978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.